Discovery of PROTAC BCL-X(L) Degraders as Potent Anticancer Agents with Low On-target Platelet Toxicity

Anti-apoptotic protein BCL-X(L) plays a key role in tumorigenesis and cancer chemotherapy resistance, rendering it an attractive target for cancer treatment. However, BCL-X(L) inhibitors such as ABT-263 cannot be safely used in the clinic because platelets solely depend on BCL-X(L) to maintain their...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Med Chem
Päätekijät: Zhang, Xuan, Thummuri, Dinesh, Liu, Xingui, Hu, Wanyi, Zhang, Peiyi, Khan, Sajid, Yuan, Yaxia, Zhou, Daohong, Zheng, Guangrong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7433031/
https://ncbi.nlm.nih.gov/pubmed/32145645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2020.112186
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia